ETH 168
Alternative Names: ETH-168Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator Shengke Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Tropomyosin-related kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 25 Aug 2023 ETH 168 is available for licensing as of 25 Aug 2023. https://www.shengketx.com/pipeline/
- 24 Jul 2023 Early research in Solid tumours in China (unspecified route) (Shengke Pharmaceuticals pipeline, July 2023)